Ongoing Litigation Regarding the Use of Cow's Milk Formulas and Necrotizing Enterocolitis: Issues of Product Liability and Proposed Requirement for Informed Consent.

IF 2.1 3区 医学 Q2 OBSTETRICS & GYNECOLOGY
T Allen Merritt, Kimberly Hillyer, Mitchell Goldstein, Joseph Hageman
{"title":"Ongoing Litigation Regarding the Use of Cow's Milk Formulas and Necrotizing Enterocolitis: Issues of Product Liability and Proposed Requirement for Informed Consent.","authors":"T Allen Merritt, Kimberly Hillyer, Mitchell Goldstein, Joseph Hageman","doi":"10.1089/bfm.2024.0321","DOIUrl":null,"url":null,"abstract":"<p><p>Recent litigation against the two major U.S. formula manufacturers regarding their products liability, in Gill v Abbott Laboratories and Watson v Mead Johnson, juries in two U.S. states have determined that these manufacturers' created products liability by their failure to warn parents and medical professionals that their formulas posed an increased risk for necrotizing enterocolitis (NEC). They asserted that their products are safe and effective. Juries in state courts in both cases awarded substantial monetary awards for punitive damage, economic and emotional harms to parents whose infant died after being fed \"premature special care formulas.\" The company's defense attorneys unsuccessfully asserted the doctrine of learned intermediaries, namely that it was neonatologists who ordered and/or administered these products to premature infants, thus causing NEC. The Food and Drug Administration (FDA) has regulatory authority over the formula manufacturing processes but does not grant \"approval\" status, as the FDA classifies these \"special care formulas\" as exempt because they are nutritional agents. While both cases are being appealed, the impact of these legal actions may discourage further \"special care formula\" development and may pose the future risk of physician malpractice allegations when an infant develops NEC after receiving a \"special care formula.\" In accordance with American Academy of Pediatrics recommendations, obtaining informed consent for formula use may mitigate some legal risks for neonatologists and other medical providers.</p>","PeriodicalId":9142,"journal":{"name":"Breastfeeding Medicine","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breastfeeding Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/bfm.2024.0321","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Recent litigation against the two major U.S. formula manufacturers regarding their products liability, in Gill v Abbott Laboratories and Watson v Mead Johnson, juries in two U.S. states have determined that these manufacturers' created products liability by their failure to warn parents and medical professionals that their formulas posed an increased risk for necrotizing enterocolitis (NEC). They asserted that their products are safe and effective. Juries in state courts in both cases awarded substantial monetary awards for punitive damage, economic and emotional harms to parents whose infant died after being fed "premature special care formulas." The company's defense attorneys unsuccessfully asserted the doctrine of learned intermediaries, namely that it was neonatologists who ordered and/or administered these products to premature infants, thus causing NEC. The Food and Drug Administration (FDA) has regulatory authority over the formula manufacturing processes but does not grant "approval" status, as the FDA classifies these "special care formulas" as exempt because they are nutritional agents. While both cases are being appealed, the impact of these legal actions may discourage further "special care formula" development and may pose the future risk of physician malpractice allegations when an infant develops NEC after receiving a "special care formula." In accordance with American Academy of Pediatrics recommendations, obtaining informed consent for formula use may mitigate some legal risks for neonatologists and other medical providers.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Breastfeeding Medicine
Breastfeeding Medicine OBSTETRICS & GYNECOLOGY-PEDIATRICS
CiteScore
4.20
自引率
11.10%
发文量
130
审稿时长
6-12 weeks
期刊介绍: Breastfeeding Medicine provides unparalleled peer-reviewed research, protocols, and clinical applications to ensure optimal care for mother and infant. The Journal answers the growing demand for evidence-based research and explores the immediate and long-term outcomes of breastfeeding, including its epidemiologic, physiologic, and psychological benefits. It is the exclusive source of the Academy of Breastfeeding Medicine protocols. Breastfeeding Medicine coverage includes: Breastfeeding recommendations and protocols Health consequences of artificial feeding Physiology of lactation and biochemistry of breast milk Optimal nutrition for the breastfeeding mother Breastfeeding indications and contraindications Managing breastfeeding discomfort, pain, and other complications Breastfeeding the premature or sick infant Breastfeeding in the chronically ill mother Management of the breastfeeding mother on medication Infectious disease transmission through breast milk and breastfeeding The collection and storage of human milk and human milk banking Measuring the impact of being a “baby-friendly” hospital Cultural competence and cultural sensitivity International public health issues including social and economic issues.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信